Condition
Cerebral Adrenoleukodystrophy
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Withdrawn1
Suspended1
Unknown1
Recruiting1
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06030648Phase 1SuspendedPrimary
MT2022-01: MSCs for ALD
NCT03789721Recruiting
Adrenoleukodystrophy National Registry Study
NCT03367546Phase 2Terminated
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases
NCT04528706Phase 2UnknownPrimary
A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)
NCT02410239Phase 1WithdrawnPrimary
MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)
Showing all 5 trials